Research programme: Duchenne muscular dystrophy - Atlantic Gene Therapies/Genethon/Institute of Myology
Latest Information Update: 19 Nov 2014
At a glance
- Originator Genethon
- Developer Atlantic Gene Therapies; Genethon; Institut de Myologie
- Class Gene therapies
- Mechanism of Action Dystrophin expression stimulants; Gene transference
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Duchenne muscular dystrophy
Most Recent Events
- 10 Nov 2014 Preclinical trials in Duchenne muscular dystrophy in France (IM)